Advertisement

Lone Atrial Fibrillation: Prophylactic Anti-arrhythmic Treatment

  • Gianluca Botto
  • Mario Luzi
  • Giovanni Russo
  • Barbara Mariconti
Conference paper

Abstract

Atrial fibrillation is a common arrhythmia and the cause of substantial morbidity [1, 2]. Management strategies for its control are far from satisfactory [3]. Most importantly, whether by restoring sinus rhythm or by controlling ventricular rate, arrhythmic strategies bring with them a proarrhythmic or arrhythmogenic risk [4]. In such cases, the basic arrhythmia may be aggravated or new and more devastating arrhythmia may be produced.

Keywords

Atrial Fibrillation Structural Heart Disease Sinus Node Dysfunction Proarrhythmic Event Maintain Sinus Rhythm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Feinberg WM, Blackshear JL, Laupacis A et al (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155:469–574PubMedCrossRefGoogle Scholar
  2. 2.
    Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 114: e257–e354PubMedCrossRefGoogle Scholar
  3. 3.
    Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. N Engl J Med 347:1825–1833PubMedCrossRefGoogle Scholar
  4. 4.
    Falk RH (1992) Proarrhythmia in patients treated for atrial fibrillation. Ann Int Med 117:141–150PubMedGoogle Scholar
  5. 5.
    The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406–412CrossRefGoogle Scholar
  6. 6.
    Prystowsky EN (1996) Proarrhythmia during treatment for supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. Am J Cardiol 78:35–41PubMedCrossRefGoogle Scholar
  7. 7.
    Coplen SE, Antman EM, Berlin JA et al (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta analysis of randomized, controlled trial. Circulation 82:1106–1116PubMedGoogle Scholar
  8. 8.
    Minardo JD, Heger JJ, Miles WE et al (1988) Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med 319:257–262PubMedCrossRefGoogle Scholar
  9. 9.
    Capucci A, Villani GQ, Aschieri D et al (1998) Effects of class III drugs on atrial fibrillation. J Cardiovasc Electrophysiol 9:109–120CrossRefGoogle Scholar
  10. 10.
    Camm AJ, Yap YG (1999) What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol 10:307–317PubMedCrossRefGoogle Scholar
  11. 11.
    Levy D, Anderson KM, Savage DD et al (1987) Risk of ventricular arrhyhtmia in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 60:560–565PubMedCrossRefGoogle Scholar
  12. 12.
    Roden DM (1994) Risk and benefit of antiarrhyhtmic therapy. N Engl J Med 331:785–791PubMedCrossRefGoogle Scholar
  13. 13.
    Botto GL, Bonini W, Broffoni T et al (1994) Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. Pacing Clin Electrophysiol 11:2114–2117CrossRefGoogle Scholar
  14. 14.
    Capucci A, Villani GQ, Aschieri D et al (2000) Oral amiodarone increase the efficacy of DC-cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 21:66–73PubMedCrossRefGoogle Scholar
  15. 15.
    Steinberg JS, Sadaniantz A, Kron J et al (2004) Analysis of cause specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 109:1973–1980PubMedCrossRefGoogle Scholar
  16. 16.
    Kaufman ES, Zimmermann PA, Wang T et al (2004) Risk of proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. J Am Coll Cardiol 44:1276–1282PubMedGoogle Scholar
  17. 17.
    Disertori M, Alboni P, Botto GL et al (2006) Linee guida AIAC 2006 sul trattamento della fibrillazione atriale. Giornale Italiano di Aritmologia e Cardiostimolazione 9:1–71Google Scholar
  18. 18.
    Reimold SC, Cantrillon CO, Friedman PL et al (1993) Propafenone versus sotalol in suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 71:558–563PubMedCrossRefGoogle Scholar
  19. 19.
    Cappato R, Calkins H, Chen SA et al (2005) Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111:1100–1105PubMedCrossRefGoogle Scholar
  20. 20.
    Naccarelli GV, Dell’Orfano JT, Wolbrette DL et al (2000) Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and anti embolic therapy. Am J Car diol 85:36D–45DCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • Gianluca Botto
    • 1
  • Mario Luzi
    • 1
  • Giovanni Russo
    • 1
  • Barbara Mariconti
    • 1
  1. 1.Department of CardiologySant’Anna HospitalComoItaly

Personalised recommendations